ImmPACT Bio racks up $111m Series B
ImmPACT Bio, a developer of transformative logic-gate based chimeric antigen receptor T-cell therapies for treating cancer, has raised $111 million in Series B financing.
ImmPACT Bio, a developer of transformative logic-gate based chimeric antigen receptor T-cell therapies for treating cancer, has raised $111 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination